185 related articles for article (PubMed ID: 17116336)
1. The acyclic nucleoside phosphonates from inception to clinical use: historical perspective.
De Clercq E
Antiviral Res; 2007 Jul; 75(1):1-13. PubMed ID: 17116336
[TBL] [Abstract][Full Text] [Related]
2. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines.
De Clercq E; Andrei G; Balzarini J; Leyssen P; Naesens L; Neyts J; Pannecouque C; Snoeck R; Ying C; Hocková D; Holý A
Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):331-41. PubMed ID: 16247948
[TBL] [Abstract][Full Text] [Related]
3. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge.
De Clercq E
Biochem Pharmacol; 2007 Apr; 73(7):911-22. PubMed ID: 17045247
[TBL] [Abstract][Full Text] [Related]
4. The acyclic nucleoside phosphonates (ANPs): Antonín Holý's legacy.
De Clercq E
Med Res Rev; 2013 Nov; 33(6):1278-303. PubMed ID: 23568857
[TBL] [Abstract][Full Text] [Related]
5. Acyclic nucleoside phosphonates: a key class of antiviral drugs.
De Clercq E; Holý A
Nat Rev Drug Discov; 2005 Nov; 4(11):928-40. PubMed ID: 16264436
[TBL] [Abstract][Full Text] [Related]
6. Ten paths to the discovery of antivirally active nucleoside and nucleotide analogues.
De Clercq E
Nucleosides Nucleotides Nucleic Acids; 2012 Apr; 31(4):339-52. PubMed ID: 22444195
[TBL] [Abstract][Full Text] [Related]
7. Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday.
Li G; Yue T; Zhang P; Gu W; Gao LJ; Tan L
Molecules; 2021 Feb; 26(4):. PubMed ID: 33572409
[TBL] [Abstract][Full Text] [Related]
8. The Holý Trinity: the acyclic nucleoside phosphonates.
De Clercq E
Adv Pharmacol; 2013; 67():293-316. PubMed ID: 23886004
[TBL] [Abstract][Full Text] [Related]
9. [Design, synthesis and anti-HBV activity of L-amino acid ester prodrugs of acyclic nucleoside phosphonates].
Fu XZ; Jiang SH; Yang YS; Ji RY
Yao Xue Xue Bao; 2008 May; 43(5):495-503. PubMed ID: 18717337
[TBL] [Abstract][Full Text] [Related]
10. Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections.
De Clercq E
Expert Rev Anti Infect Ther; 2003 Jun; 1(1):21-43. PubMed ID: 15482100
[TBL] [Abstract][Full Text] [Related]
11. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.
De Clercq E
Clin Microbiol Rev; 2003 Oct; 16(4):569-96. PubMed ID: 14557287
[TBL] [Abstract][Full Text] [Related]
12. Antiviral acyclic nucleoside phosphonates structure activity studies.
Holý A
Antiviral Res; 2006 Sep; 71(2-3):248-53. PubMed ID: 16857275
[TBL] [Abstract][Full Text] [Related]
13. The Elegance of the Acyclic Nucleoside Phosphonates (ANPs), Honorary Tribute to Antonín Holý, Who Passed Away on 16 July 2012, at the 10th Anniversary of His Death.
De Clercq E
Viruses; 2022 Sep; 14(9):. PubMed ID: 36146783
[TBL] [Abstract][Full Text] [Related]
14. Antiviral activities of novel 5-phosphono-pent-2-en-1-yl nucleosides and their alkoxyalkyl phosphonoesters.
Choo H; Beadle JR; Kern ER; Prichard MN; Keith KA; Hartline CB; Trahan J; Aldern KA; Korba BE; Hostetler KY
Antimicrob Agents Chemother; 2007 Feb; 51(2):611-5. PubMed ID: 17130297
[TBL] [Abstract][Full Text] [Related]
15. The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: the magic of the phosphonate bond.
De Clercq E
Biochem Pharmacol; 2011 Jul; 82(2):99-109. PubMed ID: 21501598
[TBL] [Abstract][Full Text] [Related]
16. Antiviral drug discovery and development: where chemistry meets with biomedicine.
De Clercq E
Antiviral Res; 2005 Aug; 67(2):56-75. PubMed ID: 16046240
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir for the treatment of hepatitis B virus.
Jenh AM; Thio CL; Pham PA
Pharmacotherapy; 2009 Oct; 29(10):1212-27. PubMed ID: 19792994
[TBL] [Abstract][Full Text] [Related]
18. Pronounced in vitro and in vivo antiretroviral activity of 5-substituted 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy] pyrimidines.
Balzarini J; Schols D; Van Laethem K; De Clercq E; Hocková D; Masojidkova M; Holý A
J Antimicrob Chemother; 2007 Jan; 59(1):80-6. PubMed ID: 17124193
[TBL] [Abstract][Full Text] [Related]
19. Ester prodrugs of acyclic nucleoside thiophosphonates compared to phosphonates: synthesis, antiviral activity and decomposition study.
Roux L; Priet S; Payrot N; Weck C; Fournier M; Zoulim F; Balzarini J; Canard B; Alvarez K
Eur J Med Chem; 2013 May; 63():869-81. PubMed ID: 23603046
[TBL] [Abstract][Full Text] [Related]
20. Looking back in 2009 at the dawning of antiviral therapy now 50 years ago an historical perspective.
De Clercq E
Adv Virus Res; 2009; 73():1-53. PubMed ID: 19695380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
